NB-001 in Children and Adolescents With 22q11 Deletion Syndrome

NCT05290493 PHASE2 COMPLETED Results posted

This is a Phase 2, randomized, placebo-controlled crossover trial to assess the safety and efficacy of NB-001 in children and adolescents with 22q11DS that manifest commonly associated neuropsychiatric symptoms.

Details

Lead sponsor	Nobias Therapeutics, Inc.
Phase	PHASE2
Status	COMPLETED
Enrolment	37
Start date	Thu Feb 10 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jun 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• 22q11 Deletion Syndrome

Interventions

• NB-001
• Placebo

Countries

Canada, United States